The KLC4 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-mediated gene-disrupted population derived from the NCI-H1975 human lung adenocarcinoma cell line, targeting the KLC4 locus that encodes a kinesin light chain subunit. This ready-to-use polyclonal knockout cell model enables loss-of-function analysis without additional cloning or selection steps. The pooled population contains heterogeneous edits across the target gene, representing a practical tool for studying gene function in a cancer-relevant background.
The NCI-H1975 host cell line originates from a non-smoking female patient with non-small cell lung adenocarcinoma and harbors activating L858R and resistance-associated T790M mutations in the epidermal growth factor receptor (EGFR). This genetic context renders NCI-H1975 a widely employed model for investigating EGFR-targeted therapy resistance, particularly against first- and third-generation tyrosine kinase inhibitors. The line exhibits epithelial morphology and stable growth characteristics suitable for in vitro assays.
KLC4 functions as a light chain component of the heterotetrameric kinesin-1 motor, partnering with the heavy chain KIF5B to drive anterograde transport along microtubules. It acts as a cargo-binding adaptor, linking the motor to intracellular cargoes through interactions with JIP1, JIP3, 14-3-3 proteins, and huntingtin-associated protein 1 (HAP1). This mechanism mediates trafficking of mitochondria, lysosomes, and signaling molecules such as the TrkB neurotrophin receptor, amyloid precursor protein (APP), and ??-catenin. Upstream kinases including GSK3??, JNK, and CDK5 phosphorylate KLC4 to regulate cargo binding and release, thereby integrating transport with EGFR, Wnt, and integrin signaling pathways.
In NCI-H1975 cells, disruption of KLC4 is predicted to perturb microtubule-based delivery of signaling regulators, potentially impairing EGFR trafficking, downstream kinase activation, and focal adhesion dynamics. Given the cell line??s reliance on sustained EGFR signaling, KLC4 knockout may alter proliferation, migration, and drug sensitivity. This model thus provides a relevant context to dissect how transport processes intersect with oncogenic signaling in lung adenocarcinoma.
Research applications include dissecting intracellular transport pathways in lung cancer, elucidating EGFR resistance mechanisms, and screening for compounds that modulate cargo trafficking. Representative assays for this model are western blotting and RT-qPCR for KLC4 expression confirmation, immunofluorescence-based analysis of mitochondrial and lysosomal positioning, microtubule-dependent transport assays, wound-healing migration tests, and drug sensitivity profiling with EGFR inhibitors such as osimertinib. For additional technical information, please contact Ascent Research.
